Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND PLUS
NCT05441267Phase 4Active, not recruiting
- Sponsor
- University of Oxford
- Start
- Mar 2023
- Primary completion
- Aug 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by University of Oxford. Started Mar 2023; status: active, not recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05441267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05441267.